 

Active ingredient: Armodafinil 

 

Form/Route: Tablets/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-treatment, two-period crossover in-vivo 

Strength: 250 mg 

Subjects: Normal healthy males and females, general population. 

Additional Comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-treatment, two-period crossover in-vivo 

Strength: 250 mg 

Subjects: Normal healthy males and females, general population. 

Additional Comments: 




______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Armodafinil in plasma. 

 

Bioequivalence based on (90% CI): Armodafinil 

 

Waiver request of in-vivo testing: 50 mg and 150 mg, based on acceptable (i) bioequivalence 
studies on the 250 mg strength, and (ii) proportional similarity of the formulations and (iii) 
acceptable in vitro dissolution testing of all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 


